Literature DB >> 23011837

Mixture of three amino acids as stabilizers replacing albumin in lyophilization of new third generation recombinant factor VIII GreenGene F.

Sang Hoon Paik1, Yong Jae Kim, Sang Kyul Han, Jean Man Kim, Jae Wook Huh, Young In Park.   

Abstract

A formulation with stabilizers replacing albumin was developed for lyophilization of recombinant factor VIII (FVIII), GreenGene F (WHO INN: beroctocog alfa), to achieve stability and eliminate safety issues of blood-derived albumin. L-Arginine (hydrophilic amino acid, positively charged side chain), L-glutamic acid (hydrophilic amino acid, negatively charged side chain), and L-isoleucine (hydrophobic amino acid, nonpolar) were selected as stabilizers, and the mixture of the three amino acids were optimized. The mixture had results comparative with albumin and other commonly used stabilizers showing good preservation of recombinant FVIII during lyophilization, robust stability with consistently high recovery of FVIIII, very low aggregate formation, and good storage stability without alterations in protein characteristics. In vivo test results showed that the efficacy was maintained and had no signs of toxicity. The study demonstrated that the three amino acid mixture acts as a good stabilizer for lyophilization of recombinant FVIII and as a safe excipient.
Copyright © 2012 American Institute of Chemical Engineers (AIChE).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23011837     DOI: 10.1002/btpr.1640

Source DB:  PubMed          Journal:  Biotechnol Prog        ISSN: 1520-6033


  5 in total

Review 1.  Advanced protein formulations.

Authors:  Wei Wang
Journal:  Protein Sci       Date:  2015-05-01       Impact factor: 6.725

2.  Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A.

Authors:  Shin Young Hyun; Seon Yang Park; Soon Yong Lee; Hoon Kook; Sang Hoon Paik; In-Jin Jang; Kun Soo Lee
Journal:  Yonsei Med J       Date:  2015-07       Impact factor: 2.759

3.  Stability enhancement in a mAb and Fab coformulation.

Authors:  Hongyu Zhang; Paul A Dalby
Journal:  Sci Rep       Date:  2020-12-03       Impact factor: 4.379

4.  Recombinant phosphatidylserine-binding nanobodies for targeting of extracellular vesicles to tumor cells: a plug-and-play approach.

Authors:  Sander A A Kooijmans; Jerney J J M Gitz-Francois; Raymond M Schiffelers; Pieter Vader
Journal:  Nanoscale       Date:  2018-02-01       Impact factor: 7.790

5.  Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.

Authors:  Soon Ki Kim; Ki Young Yoo; Kun Soo Lee; Taiju Hwang; Yong Mook Choi; Eun Jin Choi; Sang Kyu Park
Journal:  J Korean Med Sci       Date:  2018-01-01       Impact factor: 2.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.